PDCD1 and neoplasm: Overall,this tunable platform supports co-delivery of proteins and small moleculesincludingGOx, TRAIL, DOX, and anti-PD-1 antibodieswhile maintainingbioactivity, and its modular, tumor-responsive design supports clinicaltranslation for multimodal cancer therapy.